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Case Implant rehabilitation in patients suffering from rheumatoid arthritis (RA) has been reported an improvement in the quality of life. 
Implant treatment success depends on many factors like achievement of appropriate osseointegration. There are many controversies 
about the interactions between anti-rheumatic drugs and osseointegration. Moreover, the scientific evidence regarding implant 
survival in RA patients are scarce. This study presents two case reports including 65- and 51-year-old women who have used low-dose 
methotrexate and other anti-rheumatic drugs treated by dental implants. After 4-years follow-up, the patients are satisfied of function 
and aesthetics. Stable bone level was seen around all implants radiographically. Because of the lack of agreement in implant treatment 
protocol in RA patient, more studies are suggested.
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Introduction
Dental implants are considered as a valuable treatment in resto-
ration of edentulous area. Intraosseous implant success mainly 
depends on a definition named osseointegration that is a con-
structional and functional connection between the living bone 
and the implant surfaces.1 The mechanism of the mentioned 
phenomenon is similar to the bone remodeling and its repair. 
Bone remodeling described as a dynamic bone resorption pro-
cess by osteoclasts and new bone formation by osteoblasts.2 
Therefore, factors which disturb the remodeling and bone repair 
procedure can end in osseointegration failure.3Rheumatoid 
arthritis is a systemic autoimmune disease that can cause hard 
and soft tissue injuries, pain, swelling, and limited movement of 
joint are deemed prevalent complications of the problem.4 In 
order to relieve symptoms, patients were obliged to use long-
term multiple medications including methotrexate (MTX),5 
glucocorticoid,6,7 sulfasalazine,8 nonsteroidal anti-inflammatory 
drug (NSAID),9 Remicade and so forth. Such combination of 
drugs may interfere with bone repair and osseointegration.3
For instance, several studies have shown bone resorption 
and reduction new bone synthesis in long-term use of gluco-
corticoids, while other investigations have revealed evidence 
which suggests that when osseointegration is obtained, the use 
of glucocorticoid cannot cause osseointegration failure. Such 
controversy has also been proposed about NSAIDs and MTX.9
There are disagreements regarding the effects of low-dose 
MTX widely used in rheumatoid arthritis (RA) on bone 
metabolism. Many studies show the osteopathy resulting from 
long-term use of this drug, on the other hand, a protective 
effect on bone metabolism have reported for MTX that pre-
vents bone generalized resorption.3,4,10,11
In fact, it has to be said that there are not much scientific 
evidences about the survival rate of the implants in patients 
with rheumatoid arthritis. So a question comes to mind 
whether RA and anti-rheumatic drugs can be a real contrain-
dication for the implant treatment in these patients?
This study shows a successful 4-years follow-up period of 
implant loading and osseointegration in two arthritis rheuma-
toid patients who have used anti-rheumatic drugs for long 
term. It may be an answer to this question. Certainly, further 
studies with large number of patients and implants and longer 
follow-up can prove the results.
Case One
A fully edentulous 65-year-old woman who has used tissue 
supported complete denture, but loosed because of the 
 moderate to severe maxillary and mandibular alveolar ridge 
resorption, referred to our clinic. According to the 
 rheumatologist and internist administration, she has con-
sumed prednisolone (AbuReyhan, Iran) 5 mg daily, MTX 
(Zahravi, Iran) 2.5 mg twice a week for a period of 14.5 years 
and two tablets of metformin 500 mg for 12.5 years to control 
her diabetes. Except of the mentioned information, patient 
had no other systemic problems.
After consultation with rheumatologist and internist and lab-
oratory tests, she became acceptable for implant treatment which 
was determined as implant supported over dentures based on 
bone condition, prosthodontist order, and economic situation of 
patient. Then, she signed the consent form and a CBCT was taken 
for the precise positioning of the eight implants in the specified 
area. Before the surgery, mouth was rinsed with 0.12% chlorhex-
idine mouthwash (Iran Najo, Iran). Local anesthesia was gained 
with 2% lidocaine with epinephrine 1:80,000 (Persocaine-E, 
Darou-Paksh, Iran). Standard mucoperiostal flaps were reflected 
and eight  Biodenta implants (Biodenta tissue level, Swiss AG) 
were placed including four implants in the maxilla and four 
implants in the mandible. The implant sites were prepared by sur-
gical drills with enough irrigation and eight fixtures with 3.7-mm 
diameter, were placed in ABDE positions. The  surgical  process 
was single-stage and wounds were sutured normally with Vicryl 
4-0 (Ethicon, Johnson & Johnson, NJ) and removed after 10 days. 
Amoxicillin 500 mg every 8 h (Farabi, Iran) and Novafen (Aceta-
minophen 325 mg, caffeine 40 mg, Ibuprofen 200 mg—Alhavi, 
Iran) for relieving pain were  prescribed for 1 week. During the 
preliminary healing period, the patient is advised to rinse her 
mouth two times a day with chlorhexidine 0.12% (IranNajo, Iran).
After 4 months unloading phase, all implants were inte-
grated. Bar and ball attachment were tightened. Finally, 
overdenture restorations were fabricated and loaded (Fig. 1).
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sutured with cut chromic 4-0 (Supa, Iran). For the first week 
after surgery, amoxicillin 500 mg every 8 h (Farabi, Iran), 
Novafen (Acetaminophen 325 mg, caffeine 40 mg, Ibuprofen 
200 mg—Alhavi, Iran) for relieve pain were prescribed. During 
the wound healing phase, the patient rinsed her mouth with 
chlorhexidine 0.12% (IranNajo, Iran) twice a day.
After 4 months unloading phase, we ensured of osseointe-
gration by performing clinical examination and X-ray obser-
vations. In the second-stage healing, caps were tightened. After 
sufficient healing of the gums and formation of the gingival 
ring, patient was referred to prosthodontist to start impression 
and laboratory process. Fixed crowns and bridges were made 
and loaded. (Fig. 2) After 3 years of loading, a 2–3 mm vertical 
bone loss was seen just around the upper right first and second 
molar implants and no other implants, in regular clinical and 
radiographical examination. Despite this, all implants are still 
stable and functional.
Discussion
This present study revealed successful osseointegration of 
dental implants in two RA patients under long-term use of 
multiple anti-rheumatoid drugs, which are able to interfere 
with osseointegration.3
A series of chemical mediators, including TNF-a, 
cytokines (interleukins 1 and 6, etc.)12 and prostaglandins are 
the cause of the RA symptoms (joint pain, inflammation, 
swelling, and stiffness).13 To relieve symptoms in these patients, 
a combination of drugs, such as low dose of MTX, glucocorti-
coids, sulfasalazine, NSAID, Remicade and … is prescribed 
for long time to block the action of chemical mediators.13,14
Methotrexate inhibits purine synthesis that leads to the 
accumulation of adenosine,4,15,16 also prevents T-cell activity. 
Moreover, it inhibits binding of IL-1 to its receptor on the target 
cell. In these ways, MTX reveals its anti-inflammatory effects.17
Remicade (Infliximab) inhibits TNF-a action. Adverse 
effects of this drug are serious infections like TB, fungal, viral, and 
Case Two
A 51-year-old woman suffering from severe RA with a history 
of total joint replacement in her left knee (TJR: total joint 
replacement) was referred to our clinic. She missed a number of 
teeth #2, 3, 18, 19, 29, 30, so came  to the hospital to replace 
them with implants. According to the patient’s rheumatologist 
prescription, she has consumed 5 mg of prednisolone ( Nisopred, 
Iranhormone, Iran) daily and 2.5 mg of MTX (Ebetrex Pharma, 
Austeria) two times a week for 13 years, sulfasalazine (Iwata, 
Cadila, India) 500 mg twice a day for 10 years, 5 mg/day 
Apo-Glyburide (Apotex inc, Canada) and 50 mg Sitagliptin/day 
(Ziptin, Abidi, Iran) and 500 mg/day Metformin (Glucophage, 
Actoverco, Iran) daily as anti-diabetes medications and vitamin 
D3 50000 IU/week (Zahravi, Iran). Furthermore, in the patient’s 
past medical history there was a period of 30 months chemo-
therapy from 1355 to 1388 and after that, she has used IV infu-
sion of 400 mg Remicide (Behestan darou, Iran) vials every 2 
months. She had no any other systemic problem. So she was 
suggested for implant treatment. Consultation with her rheu-
matologist, showed that there was no obstacle for implant 
treatment. She signed a consent form based on the treatment 
plan agreed by the prosthodontist.
Premedication was performed, mouth rinsed with 
 chlorhexidine 0.12% (Iran Najo, Iran), specified areas were 
numbed with lidocaine 2% and epinephrine 1/80,000 (Perso-
caine-E, Darou-Paksh, Iran). Then standard mucoperiosteal 
flaps were retracted, five Biodenta tapered fixtures (Biodenta, 
Swiss AG, Switzerland) were installed in the areas of missing 
teeth #2, 3, 18, 19, 29 in healed bone.
The tooth #31 was removed and in the same appointment, 
a SIC Bone level fixture (SIC Invent AG, Switzerland) placed in 
the mesial socket of the extracted tooth. Some allograft (Ceno-
Bone DFDBA, Tissue Regeneration Co., Iran) material was 
packed around the fixture to fill the gaps. Then, flap was 
released and 1 × 1 cm2 collagen membrane (Cenomembrane, 
Tissue Regeneration Co., Iran) was placed and the wound was 
Fig 1. (a) Mandibular atrophic alveolar ridge, (b) maxillary alveolar ridge, (c) CBCT of lower jaw 
before surgery, (d) CBCT of upper jaw before surgery, (e) implant placement, (f) panoramic radiogra-
phy 6 months after surgery, (g) bar and ball attachment of mandible, (h) bar and ball attachment of 
maxilla, (i) maxillary and mandibular removable overdentures.
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bacterial.13Sulfasalazine and NSAID inhibit cyclooxygenase and 
lipoxygenase enzymes and prevent the synthesis of prostaglan-
dins.8,9It has to be mentioned that there is a controversy about the 
effects of these drugs on bone metabolism.3 An in vitro study 
which investigated the effects of low dose of MTX on bovine oste-
oblasts, as an important part of bone remodeling, showed that 
MTX prohibited the differentiation of osteoblasts. This can have a 
negative influence on bone healing and osseointegration.4 
Another study evaluated the effects of low-dose MTX on mice 
and concluded that long-term use of that resulted in significant 
osteoporosis by suppression of osteoblasts and stimulation of 
osteoclasts that leaded to bone resorption.5 Similarly, an article 
showed osteopenia and reduced bone growth in long-term use of 
high dose MTX in children. These complications seem to be due 
to intracellular accumulation of MTX and formation of MTX-pol-
yglutamates in the rapidly growing skeletal structures of infants 
and children.3,18 Some studies have shown that osteopathy caused 
by low-dose MTX in adult RA patient is not common finding and 
is limited to a few cases.3,19,20 The effects of MTX singly or in com-
bination with glucocorticoids on implants osseointegration 
installed in the tibia of rabbits was studied and the result showed 
that bone density around the implants and bone to implants con-
tact area in group who consumed only MTX was not consider-
able. In contrast in group who used glucocorticoid alone or with 
MTX had significant reduction on both sites.21
Glucocorticoids (GC) are also prescribed to reduce 
inflammation in RA. Studies have shown that long-term use of 
GC causes bone loss, which can have a negative effect on 
 osseointegration.9,22–28 But several studies indicated that when 
osseointegration achieved, long-term use of GC does not effect 
on it.9,29 Result of a research on the rabbit’s tibia, showed no 
 significant difference in osseointegration between a group that 
Fig 2. (a) Totally joint replacement (TJR) of the patient’s left knee with a prosthesis following severe joint destruction. (b) Preoperative 
panoramic radiography showing absent teeth. (c) Maxillary fixtures of right first and second molar. (d) Mandibular fixtures in the left first and 
second molar area. (e) Mandibular fixtures in the right second premolar and second molar area, second molar fixture was installed imme-
diately after the extraction of the tooth. (f) The panoramic radiography 6 months after surgery shows the stability of the fixtures and their 
osseointegration.
Fig 3. Case one, panoramic radiography, three and a half years after 
implant loading.
Fig 4. Case two, panoramic radiography, three and a half years after 
implant loading.
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was injected dexamethasone and the control group.9,30 Another 
study  examined the effects of steroid administration on the 
 osseointegration of dental implants placed in the rabbit’s 
 mandible and they  concluded that steroid administration 
might have less effect on implants osseointegration.9,27
Several studies showed delayed healing of bony fractures 
when NSAIDs were used.9,31,32 A negative effect of Meloxicam 
on the osseointegration of titanium implants in rats has been 
recorded.9,33 Similarly, in vivo studies on a rat tibia model 
demonstrated that administration of diclofenac delayed healing 
of peri-implant bone.9,34 However, a randomized double-blind 
control trials demonstrated that oral administration of ibu-
profen consumption in the first week after implant surgery, did 
not have significant effect on bone loss around implants.9,35
Although several studies have clearly recorded a negative 
effect of anti-rheumatic drugs on bone healing, osseointegra-
tion, and implant success, many of these were or animal 
studies, therefore, cannot be applied to humans. The success of 
implant treatment has been reported by two studies, the first 
one is an 80-year-old woman with severe osteoporosis and 
chronic polyarthritis with 5-year follow-up, and the second 
one is a 56-year-old woman with RA and long-term use of 
anti-rheumatic drug and 4-year follow-up.36,37 Another study 
including 34 patients, 25 RA patients and nine patients 
suffering from RA and concomitant connective tissue disease
(CTD), showed that implant treatment had been successful in 
RA patient, but in RA + CTD group, some problem such as 
bone loss, bleeding and pocket were seen around implants.4
  Our study indicated successful osseointegration implants 
in  two  patients  with  4-year  follow-up  that  agrees  with  the 
above studies. Another strength of our study is that study per- 
formed  in  a  human.  Of  course  further  human  clinical  trial 
studies with more patients and longer follow-up are needed to 
reinforce our results.
Conclusion
Although it seems the RA medicines are able to interfere with 
implant  osseointegration,  there  is  no  serious  risk  factor  for 
implant osseointegration in RA patient.
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